An observational study in Fibromyalgia Syndrome and Myofascial Pain Syndrome (MPS), sponsored by Istanbul Aydın University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Istanbul Aydın University · Observational
Among 195 studies in Fibromyalgia with a site in Turkey — 51 open to participants now, 55 under way, none of them phase 3. Fibromyalgia · Turkey.
Among the 195 studies in Fibromyalgia with a site in Turkey, this one is the 77th largest by enrollment of the 91 observational ones, is one of 25 that started in 2026, is one of 91 observational ones, and was the 190th registered.
1,243 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
This study's enrollment of 50 is below the median of 100 across 279 observational studies indexed under Fibromyalgia.
Browse Fibromyalgia studies →51 of the 195 studies in Fibromyalgia with a site in Turkey are open now, in 1 country. Each count lists the studies.
Of the 160 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 96 (60%) stop at 75 or younger; 14 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →195 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 25 started in 2026.
Median enrollment 52 across the 104 interventional studies, 100 across the 91 observational. Of the 126 that completed or were terminated, 3 (2%) have results posted.
1 of 195 have an industry lead sponsor. The 10 most frequent:
Istanbul Aydın University is the lead sponsor of 70 studies on the registry; 18 are open to participants now.
Istanbul Aydın University has 1 study filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
22 of the studies in Fibromyalgia with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07189247Ufuk UniversityEvaluation of Fibromyalgia Frequency and Pain Parameters in Women With Polycystic Ovary Syndrome | 2026-11-01 |
| NCT06957873Ankara Training and Research HospitalCraniovertebral Angle and Fibromyalgia Severity | 2026-11-01 |
| NCT07228897Ankara Etlik City HospitalComparison of Treadmill and Outdoor Walking in Patients With Fibromyalgia | 2026-11-01 |
| NCT07416097Izmir Democracy UniversityComparison of Multidimensional Parameters in Women With Fibromyalgia and Healthy Controls | 2026-11-15 |
| NCT07261696Nigde Omer Halisdemir UniversityThe Effects of Inspiratory Muscle Training Female Patients With Fibromyalgia | 2026-12-05 |
Among the 195 studies in Fibromyalgia with a site in Turkey, from their registry updates:
Fibromyalgia (FM) and myofascial pain syndrome (MPS) are chronic pain conditions that may share some clinical features but differ in the distribution and extent of pain and associated symptoms. The biological factors contributing to these differences remain incompletely understood.
This observational study aims to compare the distribution of two pain-related genetic variants, COMT rs4680 and IL6 rs1800795, between individuals with FM and MPS and to investigate their associations with clinical characteristics. Participants will undergo standardized clinical assessment, including measures of symptom burden, physical functioning, and energy/fatigue. In participants with MPS, musculoskeletal ultrasonography will be used as an adjunct to clinical examination to support phenotypic characterization.
Genetic analysis will be performed using DNA obtained from peripheral venous blood. COMT rs4680 and IL6 rs1800795 will be genotyped using a TaqMan probe-based real-time polymerase chain reaction method.
The study is intended to explore genotype-phenotype associations in two clinically characterized chronic pain conditions. The investigated genetic variants are not being evaluated as diagnostic tests, and no intervention is assigned as part of the study.
This comparative observational study will include 50 participants, comprising 25 individuals with fibromyalgia (FM) and 25 individuals with myofascial pain syndrome (MPS).
FM will be diagnosed according to the 2016 revised American College of Rheumatology diagnostic criteria. MPS classification will be based on a standardized sequential assessment consisting of clinical examination followed by musculoskeletal ultrasonography. Clinical examination will be performed to identify the symptomatic muscle, palpable taut band, and clinically relevant myofascial trigger point. Ultrasonography will subsequently be performed in all participants classified as having MPS and will be used as an adjunct to clinical examination rather than as a standalone diagnostic test.
Clinical assessment will include the Revised Fibromyalgia Impact Questionnaire (FIQR), Symptom Severity Scale (SSS), and the Physical Functioning and Energy/Fatigue domains of the 36-Item Short Form Health Survey (SF-36).
Peripheral venous blood samples will be obtained for DNA extraction. COMT rs4680 and IL6 rs1800795 polymorphisms will be genotyped using TaqMan probe-based real-time PCR. Genotype distributions will be compared between FM and MPS, and associations between genotype categories and clinical measures will be explored.
The study is designed as a hypothesis-driven candidate-gene association study and does not aim to establish either polymorphism as a diagnostic genetic marker.
The study population consisted of adults diagnosed with fibromyalgia (FM) or myofascial pain syndrome (MPS). The study included 50 participants, with 25 participants in each diagnostic group. FM was diagnosed according to the 2016 revised American College of Rheumatology criteria. MPS was diagnosed based on standardized clinical examination, followed by musculoskeletal ultrasonography in all participants with MPS as an adjunct to clinical assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants diagnosed with fibromyalgia according to the 2016 revised American College of Rheumatology diagnostic criteria. Participants will undergo clinical assessment and genotyping of COMT rs4680 and IL6 rs1800795.
Participants with myofascial pain syndrome identified through standardized clinical examination. Musculoskeletal ultrasonography will be performed in all participants in this group as an adjunct to clinical examination to support phenotypic characterization. Participants will undergo the same clinical assessment and genotyping of COMT rs4680 and IL6 rs1800795.
COMT rs4680
Genotype frequencies of COMT rs4680 (AA, AG, and GG) will be determined by TaqMan probe-based real-time PCR and compared between participants with fibromyalgia and myofascial pain syndrome.
Time frame: At study enrollment/baseline assessment
IL6 rs1800795 Genotype Distributions
Genotype frequencies of IL6 rs1800795 (CC, CG, and GG) will be determined by TaqMan probe-based real-time PCR and compared between participants with fibromyalgia and myofascial pain syndrome.
Time frame: At study enrollment/baseline assessment
FIQR Score
The Revised Fibromyalgia Impact Questionnaire will be used to assess symptom and functional burden. Scores will be compared between diagnostic groups and explored across genotype categories.
Time frame: At baseline assessment
Symptom Severity Scale Score
Symptom Severity Scale scores will be assessed and compared between diagnostic and genotype groups.
Time frame: At baseline assessment
SF-36 Physical Functioning Score
Physical functioning will be assessed using the Physical Functioning domain of the SF-36.
Time frame: At baseline assessment
SF-36 Energy/Fatigue Score
Energy/fatigue will be assessed using the Energy/Fatigue domain of the SF-36.
Time frame: At baseline assessment
Plan to share: No — Individual participant data will not be made publicly available because the dataset includes sensitive genetic information and the informed consent obtained from participants did not include provisions for public sharing of individual-level genetic data. Aggregated and de-identified study results will be reported in scientific publications.
No publications or documents are linked to this record.
Ran from Mar 2026 to primary completion in Jul 2026, 4 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul Aydın University